Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial
{{output}}
Background: Cytomegalovirus (CMV) is a major unrecognised cause of morbidity and mortality in infants living with HIV. Valganciclovir, an oral prodrug of ganciclovir, treats CMV in immunocompromised patients, but pharmacokinetic ... ...
